+ 1 888 391 5441

Investigation Report on China Methylcobalamin Market, 2010-2019



Peripheral neuropathy is a syndrome, which is a single or any combination form of sensory loss, muscle weakness and atrophy, decreased tendon reflex and vasomotion symptoms. The factors which lead to peripheral neuropathy are that the damage of single neural limitation is a common cause of trauma, while multiple single neuropathy occurs secondary to collagen vascular disease; Multiple neuropathy may be caused by toxins, toxic substances, nutrition deficiency, metabolic disease and malignant tumors.

Methylcobalamin, derivative of Vitamin B12, is active Vitamin B12 and the therapeutic drug of peripheral neuropathy. It can promote intraneural nucleic acid, protein and metabolism, facilitate the synthesis of DNA,RNA as well as the synthesis of lecithin lipid, which is the main component of myelin sheath, and accelerate to restore the damaged nerve tissue to improve the transformation of nerve tissue and the disturbance of metabolism. In addition, it also works on restraining unusual exciting conduction of nerve tissue.

Methylcobalamin,. whose trade name is mecobalamin, was developed by Eisai Co., Ltd. and put in the market in Japan in the middle of 1980s.In 1996, mecobalamin entered the Chinese market.

Methylcobalamin developed rapidly after entering China. Its annual sales value increased from less than 200 million CNY in 2005 to 441 million CNY in 2014, with CAGR of 12.32%. It had broad market demand in China. Eisai (Suzhou) Pharmaceutical Co., Ltd, Eisai Co., Ltd. (Japan), Jiangsu Sihuan Bioengineering Co., Ltd, Nanjing Hailing Pharmaceutical Co., Ltd. and NCPC occupy large market share, among which Eisai (Suzhou) Pharmaceutical Co., Ltd occupies most, whose annual market share of sales value was over 40% in 2014.

It is predicted that in next few years, the incidence of peripheral neuropathy in China will gradually rise, making the market scale of methylcobalamin continue to increase.

Through this report, readers can get the followings and more information:

  • Market scale of Methylcobalamin in China
  • Market Competitive pattern of Methylcobalamin in China
  • Sales price of Methylcobalamin made by different enterprises in China
  • Market outlook of Methylcobalamin in China

The author recommends the following people to purchase this report:

  • Production enterprises of methylcobalamin drugs
  • Investors/research institutions focusing on Chinese pharmaceutical market
  • If interested in Chinese pharmaceutical market, you can contact CRI for customized survey service.
Why http://www.chinamarketresearchreports.com

Investigation Report on China Methylcobalamin Market, 2010-2019


Related reports :

We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy